Dissolution refers to the process by which a solid phase (e.g., a tablet or powder) goes into a solution phase

Therefore, drug dissolution ( drug release ) is the process by which drug molecules are liberated from a solid phase and enter into a solution phase



The dissolution process is of special important in drug development process since

# **Dissolution and Solubility**

*Dissolution* is the process by which a solid drug substance becomes dissolved in a solvent over time.

*Solubility* is the mass of solute that dissolves in a specific mass or volume of solvent at a given temperature (eg, 1 g of NaCl dissolves in 2.786 mL of water at  $25 \square C$ ).

## Factors Affecting on the dissolution process

The overall rate of drug dissolution may be described by the Noyes-Whitney equation

$$\frac{dC}{dt} = \frac{DA}{h}(C_{\rm s} - C)$$

where dC/dt = rate of drug dissolution at time t, D = diffusion rate constant, A = surface area of the particle,  $C_s$  = concentration of drug (equal to solubility of drug) in the stagnant layer, C = concentration of drug in the bulk solvent, and h = thickness of the stagnant layer.



### In vitro variables

Chemical stability in dissolution media · Medium Volume pH Molarity Co-solvents, added enzymes/surfactants ·Temperature of medium Apparatus · Agitation rate .

## In vivo variables





# Rate-Limiting step for drug occurnce in systemic circulation

For solid oral, immediate-release drug products (eg, tablets, capsules), the rate processes include

- 1. Dissolution of the drug in an aqueous environment.
- 2. Absorption across cell membranes into the systemic circulation.

Note1:

The slowest step in a series of kinetic processes is called the *rate-limiting step*.

Note 2 :

- When the rate of absorption (ka) >>> rate of dissolution (Kd) so the rate limiting step is the dissolution process.
- When the rate of absorption (ka)<<< rate of dissolution (Kd) so the rate limiting step is the absorption process.

### Name of the experiment:

Dissolution testing of ACV tablet in 0.1 N HCL

#### Aim of the experiment:

Determination of the dissolution rate constant for ACV in 0.1 N HCL

#### Procedure:

- 1- Fill the Jar with 900 ml of Artificial gastric fluid
- 2- Switch on the heater contected to the water bath until the temperature of the dissolution fluid reaches to  $37^{0}$  C.
- 3- Put on tablet into the Jar and start the instrument immediately at a speed of 50 r.p. m.
- 4- Draw 5 ml after 5 ,10 ,15, 20 ,30, 40 , 50 min. from the surface of the dissolution media. Stop the apparatus while withdrawing samples. Substitute the volume each interval with 5ml fresh gastric fluid.

Note: In vivo, After dissolution, absorption will occur. In vitro dissolution testing, there is no absorption and drug will start to accumulate when saturation solubility is exceeded , therefore replacement with fresh media is required to maintain sink condition.

sink condition: drug concentration in the dissolution media should not exceeds 20% of the saturation solubility of the drug

- 5- Start the instrument again.
- 6- Analyte the withdraw samples of ACV by measuring the absorbance at 252 by using the spectrophotometer.
- 7- Calculate the concentration of the drug from the absorbance by using the calibration curve equation Y=a + b X
- 8- List the result in the following table

Collection time	Abs. (Y)	Conc. (X) in mg / ml	Amount released (mg)	% Amount released

9- Draw the following curve to calculate the dissolution rate constant



Note: According to first order reaction :

$$\log C_t = \log C_0 + \frac{k}{2.303} t$$

x- axis (t), y-axis (Log  $C_{t \, \%}$ )

Slope =  $\frac{k}{2.303}$ 

K (min  $^{-1}$  or hr  $^{-1}$ ) = Slope X 2.303

# Practical issue 1 :

In vitro dissolution can give idea about the in vivo dissolution and drug bioavailability, How? are their any challenges for establishing such correlation?

Practical issue 2 :

Tablet A and Tablet B both contain the same drug and in the same potency, will the provide similar dissolution profile or behavior upon performing in vitro dissolution testing? Explain ...

Practical issue 3 :

Rate limiting step for drug in BSC I is..... because ......, While BSC II is..... because .....